Private retinal vein occlusion injection treatment — UK 2026 medical retina pathway guide

What is retinal vein occlusion and why do injections help?

The retina drains its blood through a tree of veins that merge into the central retinal vein at the optic nerve. If a vein becomes blocked — usually by a clot or by compression where a stiffened artery crosses a vein — pressure builds up behind the blockage. Fluid and blood leak out of the congested capillaries into the retina. When this leakage reaches the macula (the central retina responsible for detailed vision), the macula swells; this macular oedema is what blurs and distorts central vision.

RVO comes in two main forms. Branch retinal vein occlusion (BRVO) blocks one tributary vein and affects a sector of the retina; it is more common and generally has a better prognosis. Central retinal vein occlusion (CRVO) blocks the main vein draining the whole retina and tends to cause more severe oedema and a higher risk of complications. A subtype, hemiretinal vein occlusion, affects half the retina. RVO is associated with high blood pressure, raised cholesterol, diabetes, glaucoma and, in younger patients, clotting tendencies — so part of management is a medical work-up to address these risk factors.

The reason injections work is that the leakage is driven largely by a chemical called vascular endothelial growth factor (VEGF), released by the oxygen-starved retina. Anti-VEGF drugs — aflibercept (Eylea), ranibizumab (Lucentis) and the newer dual-action faricimab (Vabysmo, which also blocks angiopoietin-2) — neutralise VEGF, stop the leakage and allow the macula to dry. The dexamethasone implant (Ozurdex) is a slow-release steroid that reduces inflammation and oedema and is particularly useful for patients who cannot attend frequently or who respond poorly to anti-VEGF. Laser is reserved for ischaemic and neovascular complications rather than the oedema itself.

Treatment is given as a course. A typical pathway is a loading phase of monthly injections to dry the macula, followed by a treat-and-extend regime in which the interval between injections is gradually lengthened as long as the macula stays dry on OCT. Many patients need ongoing treatment for one to two years; some can eventually stop, while others need long-term maintenance.

UK 2026 RVO injection treatment pricing, in detail

Below is a typical UK 2026 private fee structure for RVO treatment at a CQC-registered London medical retina centre. Because RVO is treated as an individualised course, ask for a written estimate of likely first-year costs based on your occlusion type and severity.

RVO sits within the wider medical retina pathway. See private anti-VEGF injections and the drug-specific cost guides for aflibercept (Eylea HD) and faricimab (Vabysmo). For ischaemic and neovascular complications see vitreoretinal surgery (for vitreous haemorrhage) and, if eye pressure rises from new vessels, neovascular glaucoma (laser glaucoma treatment).

What a quality UK RVO treatment package should include

When you read a private RVO quote, check it covers each of the following. The diagnostics and the structured follow-up matter as much as the injection itself.

• Consultant medical retina specialist — GMC-registered consultant ophthalmologist with a medical retina or vitreoretinal subspecialty interest and a substantive NHS retinal post.
• High-resolution OCT at every visit — Optical coherence tomography to measure macular thickness and decide each injection; the backbone of treat-and-extend.
• Fluorescein angiography or OCT-angiography — To distinguish ischaemic from non-ischaemic RVO and detect capillary non-perfusion, which changes prognosis and the need for laser.
• Choice of licensed drugs — Access to aflibercept, ranibizumab, faricimab and the Ozurdex implant so treatment can be tailored to your response and circumstances.
• Sterile clean-room injection environment — Injections performed under aseptic technique in a dedicated clean room or theatre to minimise endophthalmitis risk.
• Systemic risk-factor work-up — Blood pressure, cholesterol, blood glucose and, in younger patients, a thrombophilia screen, with onward referral to the GP or physician.
• Intraocular pressure monitoring — Especially with steroid implants, which can raise eye pressure; and gonioscopy to detect iris new vessels in ischaemic CRVO.
• A written treat-and-extend plan — A clear loading and maintenance schedule with defined OCT criteria for extending or shortening intervals.
• Same-week access for new or worsening symptoms — RVO and its complications are time-critical; rapid review protects vision.
• Laser capability on the same pathway — Macular grid, sectoral or panretinal photocoagulation available without onward referral if neovascular complications develop.
• CQC-registered facility — Inspected and rated on Safe and Effective domains.
• Transparent per-injection and annual cost estimate — A written projection of likely first-year treatment costs, not just a single-injection headline price.

Evidence base — what the RVO treatment literature shows

RVO injection therapy is supported by a large body of landmark randomised controlled trials that established anti-VEGF and steroid treatment as the standard of care, replacing laser for the oedema itself.

• BRAVO (ranibizumab in BRVO) — Demonstrated significant vision gains with ranibizumab for macular oedema following branch retinal vein occlusion.
• CRUISE (ranibizumab in CRVO) — Established the benefit of ranibizumab for macular oedema secondary to central retinal vein occlusion.
• COPERNICUS and GALILEO (aflibercept in CRVO) — Pivotal trials showing strong vision gains with aflibercept in CRVO macular oedema.
• VIBRANT (aflibercept in BRVO) — Confirmed aflibercept efficacy for macular oedema in branch retinal vein occlusion.
• GENEVA (dexamethasone implant in RVO) — Established the Ozurdex dexamethasone implant for macular oedema in both BRVO and CRVO.
• SCORE and SCORE2 studies — Compared treatments including triamcinolone, anti-VEGF agents and bevacizumab versus aflibercept in RVO macular oedema.
• BALATON and COMINO (faricimab in RVO) — Trials supporting dual-action faricimab for macular oedema secondary to branch and central retinal vein occlusion.
• Royal College of Ophthalmologists RVO clinical guideline — RCOphth guidance on the diagnosis, treatment and monitoring of retinal vein occlusion.
• NICE technology appraisals for anti-VEGF and Ozurdex in RVO — National Institute for Health and Care Excellence appraisals defining NHS-funded use of these therapies.
• Central Vein Occlusion Study (CVOS) legacy data — Historical natural-history and laser data that frames the modern role of laser for ischaemic and neovascular complications.

The RVO treatment options compared

Modern RVO care matches the treatment to the type of occlusion, the severity of oedema, the degree of ischaemia and your ability to attend for follow-up.

• Anti-VEGF — aflibercept (Eylea) — A first-line agent with strong CRVO and BRVO trial data; effective at drying the macula with a well-established safety profile.
• Anti-VEGF — ranibizumab (Lucentis) — The agent in the original BRAVO and CRUISE trials; effective and widely used, including biosimilar versions.
• Anti-VEGF — faricimab (Vabysmo) — A dual-action antibody blocking both VEGF and angiopoietin-2; may stabilise the vasculature and allow longer treatment intervals once dry.
• Off-label bevacizumab (Avastin) — A lower-cost anti-VEGF widely used internationally; used off-label in some settings, though licensed agents are standard in UK private practice.
• Dexamethasone implant (Ozurdex) — A slow-release intravitreal steroid lasting 3-4 months; fewer visits and useful where anti-VEGF response is poor or attendance is difficult, but raises cataract and eye-pressure risk.
• Macular grid laser (historical) — Once standard for BRVO oedema; now largely replaced by injections, which give better vision outcomes, but occasionally adjunctive.
• Sectoral or panretinal photocoagulation (PRP) — Laser to ischaemic retina to treat or prevent new-vessel growth in ischaemic RVO; targets the ischaemia and neovascular risk, not the oedema.
• Observation with risk-factor control — Mild non-ischaemic RVO without significant macular oedema may be monitored while blood pressure, cholesterol and other risk factors are optimised.
• Vitrectomy surgery — Reserved for complications such as non-clearing vitreous haemorrhage or tractional problems, not for the oedema itself.

Who is private RVO injection treatment the right choice for?

Injection therapy is indicated whenever a retinal vein occlusion causes visually significant macular oedema, and prompt treatment gives the best chance of recovering and protecting vision.

• Macular oedema on OCT after BRVO or CRVO — The core indication; central retinal thickening with reduced or distorted vision.
• Recent-onset vision loss from RVO — Early treatment, ideally within weeks, gives the best visual recovery; chronic long-standing oedema responds less well.
• Patients seeking to avoid NHS waiting times — Private pathways can start treatment within days, which matters because the macula recovers better when treated promptly.
• Patients able to commit to treat-and-extend follow-up — RVO needs a course of injections and regular OCT monitoring, often over one to two years.
• Patients who respond poorly to one drug — Switching between anti-VEGF agents or to the Ozurdex implant is part of tailored care.
• Patients for whom fewer visits are important — The Ozurdex implant suits those who cannot attend monthly, accepting the cataract and pressure trade-offs.
• Ischaemic RVO needing combined care — Those with significant capillary non-perfusion may need both injections for oedema and laser for neovascular risk.
• Patients with controllable systemic risk factors — Treating the eye alongside optimising blood pressure, cholesterol and glucose reduces the risk to the fellow eye.
• Not currently appropriate where the eye is end-stage — If long-standing ischaemia has destroyed the central photoreceptors, injections may not restore vision; this is assessed honestly at consultation.

NHS versus private RVO injection treatment

RVO treatment is available on the NHS, and NHS medical retina services use exactly the same anti-VEGF drugs, the same Ozurdex implant and the same OCT-guided treat-and-extend protocols, often delivered by the same consultants who work privately. NICE has appraised aflibercept, ranibizumab, faricimab and dexamethasone implant for NHS-funded use in RVO, so the drugs themselves are not the issue.

The difference is speed and continuity. RVO is time-sensitive: the macula recovers best when oedema is treated early, and busy NHS injection services can have delays to first appointment and, occasionally, to maintenance injections during periods of high demand. A private pathway can typically assess, scan and begin treatment within days, and can offer consistent appointment times with the same consultant throughout the treat-and-extend course. For a condition where missed or delayed injections while the macula is wet can cost vision, prompt and reliable follow-up is the principal advantage of going private.

Many patients use a hybrid approach: an urgent private assessment and loading phase to start treatment quickly, with onward transfer to NHS maintenance once the macula is dry, or vice versa. The systemic risk-factor work-up (blood pressure, cholesterol, glucose) should be coordinated with your GP regardless of where the eye treatment is delivered.

Private medical insurance and RVO injection treatment

Retinal vein occlusion is a genuine medical eye condition, so — unlike elective laser vision correction — it is generally covered by Bupa, AXA Health, Aviva, Vitality and WPA, subject to your specific policy benefits, excess and pre-authorisation. The key point to clarify is how your policy treats a condition that needs repeated, ongoing injections: some policies cover acute treatment fully but apply chronic-condition limits to long-term maintenance, and the number of injections covered per year may be capped. Pre-authorisation usually requires the consultant’s assessment letter, the OCT and angiography findings, the diagnosis and the proposed drug and CCSD procedure code; intravitreal injection and the specific drugs have established codes, and the drug is normally billed as an itemised high-cost consumable on top of the procedure. Clarify in writing, before starting, how many injections are authorised, whether switching drugs needs re-authorisation, and whether maintenance treatment beyond the first course remains covered. The clinic’s administrative team handles the submission.

Risks of intravitreal injection treatment for RVO

Intravitreal injections are among the most commonly performed procedures in ophthalmology and are very safe, but injecting into the eye carries a small, real risk that must be understood, and the steroid implant has its own profile.

• Endophthalmitis — A severe intraocular infection; very rare (around 1 in 2,000-3,000 injections) but sight-threatening, presenting at 1-5 days with pain, redness and vision loss and needing emergency treatment.
• Raised intraocular pressure — A transient rise immediately after injection, and a more sustained rise with the steroid (Ozurdex) implant in steroid-responders, managed with pressure-lowering drops.
• Cataract progression (steroid) — The Ozurdex implant accelerates cataract formation with repeated use; many treated phakic eyes eventually need cataract surgery.
• Subconjunctival haemorrhage — A harmless red patch on the white of the eye at the injection site; common and self-resolving over a week or two.
• Floaters and transient blur — Air bubbles or the drug itself can cause floaters and brief blurring after injection; usually settle within hours to days.
• Retinal tear or detachment — Very rare needle-related complications; sudden new floaters, flashes or a shadow need urgent review.
• Implant migration (Ozurdex) — Rarely, the implant can move into the front of the eye, particularly in eyes without a natural lens capsule; needs prompt management.
• Incomplete response or recurrence — Some eyes respond only partially, or the oedema recurs as the drug wears off, requiring drug switching or ongoing treatment.
• Theoretical systemic anti-VEGF risk — A small theoretical risk of systemic vascular events with anti-VEGF; carefully considered in patients with very recent stroke or heart attack.
• Treatment burden — Repeated injections and frequent visits over one to two years are demanding; this commitment is part of informed consent.

Recovery and what to expect after RVO injections

An intravitreal injection is a quick outpatient procedure. After your OCT scan and assessment, anaesthetic drops numb the eye, the eye and lids are cleaned with antiseptic, a small lid holder keeps the eye open, and the drug is injected through the white of the eye (the pars plana) with a very fine needle. The injection itself takes only seconds; the whole visit is usually under an hour including scanning and preparation. You go home the same day — no general anaesthetic, no hospital stay.

For the first few hours the eye may feel gritty or scratchy from the antiseptic, and you may see floaters or a small red patch on the white of the eye; these are normal and settle. You can usually return to normal activities the same or next day, though it is sensible to avoid swimming and very dusty environments for a couple of days and to use any lubricant drops you are given. You should not rub the eye.

The warning signs to act on are increasing pain, increasing redness, worsening vision or marked light sensitivity in the days after injection — these can indicate infection (endophthalmitis) and need same-day emergency review. You will be given a 24/7 contact route for exactly this reason.

Visually, improvement is gradual. As the macula dries over the loading phase, central vision typically sharpens and distortion lessens over weeks, with OCT scans showing the oedema settling. The treat-and-extend approach then lengthens the gap between injections as long as the macula stays dry. Many patients need ongoing treatment for one to two years; some eyes can eventually stop treatment, while others need long-term maintenance, and your consultant will track this with serial OCT.

How to choose a London clinic for RVO treatment

RVO is a long-term, OCT-driven condition, so the quality of the diagnostic imaging and the consistency of follow-up matter as much as the injection.

• Consultant medical retina specialist — A GMC-registered consultant ophthalmologist with a dedicated medical retina or vitreoretinal practice and a substantive NHS retinal post.
• High-quality OCT and angiography on site — Modern OCT, OCT-angiography and fluorescein angiography to grade oedema and ischaemia accurately at every visit.
• Full drug formulary — Access to aflibercept, ranibizumab, faricimab and the Ozurdex implant so treatment is tailored rather than one-size-fits-all.
• Dedicated clean-room injection suite — Aseptic injection environment to minimise endophthalmitis risk.
• Structured treat-and-extend protocol — A written, OCT-driven plan with the same consultant providing continuity through loading and maintenance.
• Laser and surgical backup — In-house panretinal and sectoral laser, and access to vitreoretinal surgery for complications, without onward referral.
• Systemic risk-factor coordination — A clear process for assessing and communicating blood pressure, cholesterol and glucose findings to your GP.
• Rapid access for new symptoms — Same-week or same-day review for worsening vision or possible complications.
• Transparent annual cost projection — A written estimate of likely first-year injection numbers and costs for your occlusion type.
• CQC inspection rating — Care Quality Commission report rated ‘Good’ or ‘Outstanding’ on Safe and Effective domains.

Frequently asked questions

Methodology and sources

This page is built from landmark medical retina randomised controlled trials, UK clinical guidelines and technology appraisals, and the practical experience of UK CQC-registered private medical retina services. Prices reflect typical UK 2026 self-pay rates at London retinal centres at the time of publication.

• BRAVO and CRUISE trials — ranibizumab for macular oedema in BRVO and CRVO.
• COPERNICUS and GALILEO trials — aflibercept in CRVO; VIBRANT — aflibercept in BRVO.
• GENEVA study — dexamethasone intravitreal implant (Ozurdex) in retinal vein occlusion.
• SCORE and SCORE2 studies in RVO macular oedema.
• BALATON and COMINO trials — faricimab in BRVO and CRVO.
• Royal College of Ophthalmologists Retinal Vein Occlusion clinical guideline.
• NICE technology appraisals for anti-VEGF agents and dexamethasone implant in RVO.
• Central Vein Occlusion Study (CVOS) and Branch Vein Occlusion Study (BVOS) legacy laser data.
• Endophthalmitis-after-intravitreal-injection incidence and prevention literature.
• Care Quality Commission inspection framework for ophthalmic injection providers.

This page is editorial and educational. It is not personalised medical advice. The choice of drug (aflibercept, ranibizumab, faricimab, dexamethasone implant), the treatment regime, the need for laser or surgery and the management of systemic risk factors are individual decisions made between you and a GMC-registered consultant ophthalmologist following a full assessment including OCT and angiography. Prices are typical UK 2026 ranges at CQC-registered London centres and may vary.

Book your London RVO consultation

If you have lost or distorted central vision and have been told you have a retinal vein occlusion with macular oedema, starting OCT-guided injection treatment promptly gives the best chance of recovering and protecting your sight. Our consultants are GMC-registered medical retina specialists with substantive NHS retinal posts, full access to anti-VEGF agents and the Ozurdex implant, and on-site OCT, angiography and laser. Call us or use the appointment form to arrange a same-week assessment including OCT and a clear, written treatment plan.

Related reading: Anti-VEGF injections · Aflibercept (Eylea HD) cost · Faricimab (Vabysmo) cost · Vitreoretinal surgery · Vitreous haemorrhage